Table_1_Analysis of the Status and Trends of Chinese Clinical Practice Guideline Development Between 2010 and 2020: A Systematic Review.XLSX

Objective: This study aimed to systematically review the status and trends of Chinese clinical practice guidelines (CPGs) during the time period 2010–2020 and explore their methodological characteristics. Then, based on the strengths and weaknesses in development, offer several recommendations for the quality improvement which will serve as a reference for the users and developers of CPG.Introduction: With the development of evidence-based medicine (EBM), the CPGs play an increasingly important role in healthcare decision-making both in China and worldwide.Inclusion criteria: The CPGs that have been used to help the health professionals in the healthcare decision-making were included.Methodology: The China National Knowledge Infrastructure (CNKI) and WanFang databases were searched from 2010 to 2020 for the studies describing the general and methodological characteristics of Chinese CPGs. Comparisons of the methodological characteristics between the groups were conducted using the chi-square test or Fisher's exact test. The M-K test was adopted to identify the monotonically increasing or decreasing trends of methodological characteristics over the timespan.Results: A total of 2,654 CPGs fulfilled the inclusion criteria. The quantity and quality of the guidelines developed in China have improved over the time span. From 2010 to 2020,the guidelines had differing characteristics and covered a wide range of subjects. In total, 2,318(87.34%) guidelines focused on Western Medicine. Eight (0.30%) had been developed for patient versions of guidelines, 10(0.38%) were tentative guidelines, and 16(0.60%) were rapid advice guidelines. Medical specialty societies (including their branches) (71.1%) were the main guideline makers. The most addressed diseases were neoplasms (14.43%). The target population is mainly adults (84.97%). The methodological quality of consensus-based (CB)-CPGs was obviously lower than evidence-based (EB)-CPGs. Except for the item, “recommendations were based on evidence of systematic reviews,” there were statistical differences in all other methodological items between the EB-CPGS and CB-CPGS (P < 0.01). Higher methodological quality has been observed in EB-CPGs. All the data relating to the methodological characteristics indicated that higher methodological quality was present in the guidelines using GRADE (P < 0.01).Conclusion: The quantity and quality of the guidelines developed in China have improved between 2010 and 2020. CB-CPGs have also paid attention to the methodology quality, but obviously, this is lower than that in the EB-CPGs.

研究目的：本研究旨在系统性地回顾2010年至2020年间中国临床实践指南（CPGs）的现状及发展趋势，并探讨其方法论特征。在此基础上，针对其发展过程中的优势与不足，提出若干改进质量的建议，以为指南的用户和开发者提供参考。引言：随着循证医学（EBM）的发展，CPGs在国内外医疗决策中扮演着日益重要的角色。纳入标准：纳入那些用于辅助医疗专业人员做出医疗决策的CPGs。研究方法：从2010年至2020年，通过中国知网（CNKI）和万方数据库检索描述中国CPGs的普遍性和方法论特征的文献。使用卡方检验或Fisher精确检验对各组之间的方法论特征进行比较。采用M-K测试以识别方法论特征随时间推移的单调递增或递减趋势。结果：共有2,654个CPGs符合纳入标准。在此期间，中国指南的数量和质量均有所提升。从2010年至2020年，指南具有不同的特征，覆盖了广泛的主题。总共有2,318个（87.34%）指南专注于西方医学。有8个（0.30%）是为患者版指南开发的，10个（0.38%）是临时指南，16个（0.60%）是快速咨询指南。医学专业学会（包括其分支机构）（71.1%）是主要的指南制定者。最常讨论的疾病是肿瘤（14.43%）。目标人群主要是成年人（84.97%）。基于共识的（CB）-CPGs的方法论质量明显低于基于证据的（EB）-CPGs。除“建议基于系统评价的证据”这一项外，EB-CPGs与CB-CPGs在所有其他方法论项目中均存在统计学差异（P < 0.01）。EB-CPGs中观察到了更高的方法论质量。所有关于方法论特征的数据均表明，使用GRADE的方法论质量更高。结论：2010年至2020年间，中国指南的数量和质量均有所提高。CB-CPGs也关注方法论质量，但显然，这低于EB-CPGs。